{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Longeveron Mesenchymal Stem Cells",
            "NStudiesAvail": 430108,
            "NStudiesFound": 8,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 8,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Study Group A",
                              "Study Group B",
                              "Study Group C",
                              "Study Group D",
                              "Study Group E"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.",
                              "Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.",
                              "Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A - Phase 1 (Open Label)",
                              "Cohort B - Phase 2 Treatment Group",
                              "Cohort C - Phase 2 Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "HERA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.",
                              "Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.",
                              "2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase- Cohort A",
                              "Pilot Phase Cohort B & C",
                              "Double-Blind,Randomized,Placebo Phase"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "SIRONA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs"
                        ],
                        "ArmGroupLabel": [
                              "LMSCs 10 million IV",
                              "Placebo (Plasmalyte A,HSA) IV",
                              "LMSCs 20 million IV",
                              "LMSCs100 million IV"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [
                              "RECOVER"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)",
                              "Cohort (SARS-CoV-2): Arm 2 (Placebo)",
                              "Cohort 2 (Flu): Arm 3 (LMSCs)",
                              "Cohort 2 (Flu): Arm 4 (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.",
                              "Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allo-hMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A - Allo-hMSCs",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [
                              "CRATUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.",
                              "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Placebo",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Pilot phase - Group 1",
                              "Pilot Phase - Group 2",
                              "Pilot Phase - Group 3",
                              "Randomized Phase - Group A",
                              "Randomized phase - Group B",
                              "Randomized Phase - Group C",
                              "Addendum B - Antibiotic free cell Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  }
            ]
      }
}